{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:08:35Z","timestamp":1790809715247,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bcp.2022.115373","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T10:53:52Z","timestamp":1670669632000},"page":"115373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["State of the art and perspectives in pediatric hepatocellular carcinoma"],"prefix":"10.1016","volume":"207","author":[{"given":"Graziana","family":"Digiacomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Pia","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Turrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cavazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1093526619875228","article-title":"Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update","volume":"23","author":"Ranganathan","year":"2020","journal-title":"Pediatr. Dev. Pathol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115373_b0010","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00247-021-04989-x","article-title":"Imaging and clinical features of pediatric hepatocellular carcinoma","volume":"51","author":"Arias","year":"2021","journal-title":"Pediatr. Radiol."},{"issue":"35","key":"10.1016\/j.bcp.2022.115373_b0015","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3748\/wjg.v24.i35.3980","article-title":"Pediatric hepatocellular carcinoma","volume":"24","author":"Khanna","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"43","key":"10.1016\/j.bcp.2022.115373_b0020","article-title":"V.B The future of pediatric hepatocellular carcinoma: a combination of surgical, locoregional, and targeted therapy","volume":"7","author":"Weeda","year":"2021","journal-title":"Hepatoma Res."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0025","doi-asserted-by":"crossref","first-page":"e27475","DOI":"10.1002\/pbc.27475","article-title":"Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients","volume":"66","author":"Weeda","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0030","doi-asserted-by":"crossref","first-page":"e28307","DOI":"10.1002\/pbc.28307","article-title":"Clinical heterogeneity of pediatric hepatocellular carcinoma","volume":"67","author":"D'Souza","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2022.115373_b0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cld.2018.06.008","article-title":"Pediatric Liver Tumors","volume":"22","author":"Ng","year":"2018","journal-title":"Clin. Liver Dis."},{"issue":"12","key":"10.1016\/j.bcp.2022.115373_b0040","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2022.115373_b0045","doi-asserted-by":"crossref","first-page":"e27745","DOI":"10.1002\/pbc.27745","article-title":"Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation","volume":"66","author":"Haines","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2022.115373_b0050","doi-asserted-by":"crossref","unstructured":"X. Ding, M. He, A.W.H. Chan, Q.X. Song, S.C. Sze, H. Chen, M.K.H. Man, K. Man, S.L. Chan, P.B.S. Lai, X. Wang, N. Wong, Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas, Gastroenterol. 157(6) (2019) 1630-1645 e6.","DOI":"10.1053\/j.gastro.2019.09.005"},{"issue":"11","key":"10.1016\/j.bcp.2022.115373_b0055","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.4251\/wjgo.v13.i11.1680","article-title":"Liver tumors in children with chronic liver diseases","volume":"13","author":"Sintusek","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115373_b0060","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/modpathol.2013.80","article-title":"Children's Oncology Group Liver Tumor, Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium","volume":"27","author":"Lopez-Terrada","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bcp.2022.115373_b0065","doi-asserted-by":"crossref","unstructured":"I.D. Nagtegaal, R.D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher, K.M. Washington, F. Carneiro, I.A. Cree, W.H.O.C.o.T.E. Board, The 2019 WHO classification of tumours of the digestive system, Histopathology 76(2) (2020) 182\u2013188.","DOI":"10.1111\/his.13975"},{"key":"#cr-split#-10.1016\/j.bcp.2022.115373_b0070.1","doi-asserted-by":"crossref","unstructured":"D.J. Roebuck, D. Aronson, P. Clapuyt, P. Czauderna, J. de Ville de Goyet, F. Gauthier, G. Mackinlay, R. Maibach, K. McHugh, O.E. Olsen, J.B. Otte, D. Pariente, J. Plaschkes, M. Childs, G. Perilongo, G. International Childrhood Liver Tumor Strategy, 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group, Pediatr. Radiol. 37(2) (2007) 123-132","DOI":"10.1007\/s00247-006-0361-5"},{"key":"#cr-split#-10.1016\/j.bcp.2022.115373_b0070.2","doi-asserted-by":"crossref","unstructured":"D.J. Roebuck, D. Aronson, P. Clapuyt, P. Czauderna, J. de Ville de Goyet, F. Gauthier, G. Mackinlay, R. Maibach, K. McHugh, O.E. Olsen, J.B. Otte, D. Pariente, J. Plaschkes, M. Childs, G. Perilongo, G. International Childrhood Liver Tumor Strategy, 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group, Pediatr. Radiol. 37","DOI":"10.1007\/s00247-006-0361-5"},{"key":"#cr-split#-10.1016\/j.bcp.2022.115373_b0070.3","unstructured":"(2) (2007) 123-132; quiz 249-50."},{"issue":"4","key":"10.1016\/j.bcp.2022.115373_b0075","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00247-018-4078-z","article-title":"2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)","volume":"48","author":"Towbin","year":"2018","journal-title":"Pediatr. Radiol."},{"issue":"14","key":"10.1016\/j.bcp.2022.115373_b0080","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","article-title":"Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group","volume":"18","author":"Ortega","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2022.115373_b0085","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2002.06.155","article-title":"Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study","volume":"20","author":"Katzenstein","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0676.2000.020002173.x","article-title":"Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma","volume":"20","author":"Kim","year":"2000","journal-title":"Liver"},{"issue":"9","key":"10.1016\/j.bcp.2022.115373_b0095","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s11912-022-01230-2","article-title":"Current Approaches in Hepatoblastoma-New Biological Insights to Inform Therapy","volume":"24","author":"Wu","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2022.115373_b0100","first-page":"105","article-title":"Molecular genetics of hepatocellular neoplasia","volume":"2","author":"Jain","year":"2010","journal-title":"Am. J. Transl. Res."},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0105","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jhep.2014.08.009","article-title":"The genomic landscape of hepatoblastoma and their progenies with HCC-like features","volume":"61","author":"Eichenmuller","year":"2014","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115373_b0110","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng.3547","article-title":"Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer","volume":"48","author":"Fujimoto","year":"2016","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0115","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.humpath.2008.11.005","article-title":"Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization","volume":"40","author":"Homayounfar","year":"2009","journal-title":"Hum. Pathol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115373_b0120","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00432-020-03182-1","article-title":"Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations","volume":"146","author":"Regel","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115373_b0125","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1038\/s41467-021-25430-9","article-title":"Genetic and epigenetic basis of hepatoblastoma diversity","volume":"12","author":"Nagae","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0130","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7314\/APJCP.2012.13.2.677","article-title":"Clinical significance of axin and beta-catenin protein expression in primary hepatocellular carcinomas","volume":"13","author":"Guan","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jpeds.2005.04.019","article-title":"The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds","volume":"147","author":"Hirschman","year":"2005","journal-title":"J. Pediatr."},{"issue":"31","key":"10.1016\/j.bcp.2022.115373_b0140","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1038\/sj.onc.1205591","article-title":"Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas","volume":"21","author":"Taniguchi","year":"2002","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0145","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2022.115373_b0150","article-title":"The Roles of EphB2 in Cancer","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115373_b0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1373\/clinchem.2003.026849","article-title":"Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers","volume":"50","author":"Hafner","year":"2004","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2022.115373_b0160","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/0008-5472.CAN-21-0184","article-title":"EPHB2 Activates beta-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma","volume":"81","author":"Leung","year":"2021","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.bcp.2022.115373_b0165","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3748\/wjg.v23.i24.4330","article-title":"Implication of the Hedgehog pathway in hepatocellular carcinoma","volume":"23","author":"Della Corte","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0170","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/hep.22649","article-title":"Blocking the hedgehog pathway inhibits hepatoblastoma growth","volume":"49","author":"Eichenmuller","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1872-034X.2008.00449.x","article-title":"Involvement of PI3K\/PTEN\/AKT\/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9","volume":"39","author":"Chen","year":"2009","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bcp.2022.115373_b0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-9966-32-16","article-title":"Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma","volume":"32","author":"Chu","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0185","first-page":"307","article-title":"Somatic mutations in the kinase domain of the Met\/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas","volume":"59","author":"Park","year":"1999","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2022.115373_b0190","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/pbc.23295","article-title":"Sorafenib and cisplatin\/doxorubicin (PLADO) in pediatric hepatocellular carcinoma","volume":"58","author":"Schmid","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2022.115373_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031726","article-title":"FAK in Cancer: From Mechanisms to Therapeutic Strategies","volume":"23","author":"Chuang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bcp.2022.115373_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165795","article-title":"Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma","volume":"21","author":"Francalanci","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2022.115373_b0205","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.30707","article-title":"Focal Adhesion Kinase and beta-Catenin Cooperate to Induce Hepatocellular Carcinoma","volume":"70","author":"Shang","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2022.115373_b0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MPG.0b013e31822d52cf","article-title":"Transcription factor GATA-4 is abundantly expressed in childhood but not in adult liver tumors","volume":"54","author":"Soini","year":"2012","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"10.1016\/j.bcp.2022.115373_b0215","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12032-012-0379-5","article-title":"Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma","volume":"30","author":"Lu","year":"2013","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0220","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clinre.2017.07.003","article-title":"CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis","volume":"42","author":"Zhou","year":"2018","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115373_b0225","first-page":"551","article-title":"Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors","volume":"15","author":"Yamaoka","year":"2006","journal-title":"Oncol. Rep."},{"issue":"6174","key":"10.1016\/j.bcp.2022.115373_b0230","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1249484","article-title":"Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma","volume":"343","author":"Honeyman","year":"2014","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2022.115373_b0235","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41379-019-0398-2","article-title":"DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma","volume":"33","author":"Vyas","year":"2020","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4254\/wjh.v3.i2.38","article-title":"Liver cancer: Targeted future options","volume":"3","author":"Pircher","year":"2011","journal-title":"World J. Hepatol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0245","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S2468-1253(17)30084-5","article-title":"Beyond the Milan criteria for liver transplantation in children with hepatic tumours","volume":"2","author":"de Ville","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.bcp.2022.115373_b0250","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2002.06.102","article-title":"Liver Tumors Study Group of the International Society of Pediatric, Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group","volume":"20","author":"Czauderna","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2022.115373_b0255","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2014.60.2250","article-title":"Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies","volume":"34","author":"Murawski","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2022.115373_b0260","doi-asserted-by":"crossref","first-page":"e27293","DOI":"10.1002\/pbc.27293","article-title":"Surgical management of children and adolescents with upfront completely resected hepatocellular carcinoma","volume":"65","author":"D'Souza","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2022.115373_b0265","doi-asserted-by":"crossref","first-page":"e13187","DOI":"10.1111\/petr.13187","article-title":"Transarterial chemoembolization in children to treat unresectable hepatocellular carcinoma","volume":"22","author":"Weiss","year":"2018","journal-title":"Pediatr. Transplant."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0270","first-page":"37","article-title":"Non-resectable hepatic tumors in children - role of liver transplantation","volume":"13","author":"Kalicinski","year":"2008","journal-title":"Ann. Transplant."},{"key":"10.1016\/j.bcp.2022.115373_b0275","doi-asserted-by":"crossref","unstructured":"M.M. Malek, S.R. Shah, P. Atri, J.L. Paredes, L.A. DiCicco, R. Sindhi, K.A. Soltys, G.V. Mazariegos, T.D. Kane, Review of outcomes of primary liver cancers in children: our institutional experience with resection and transplantation, Surgery 148(4) (2010) 778\u2013782; discussion 782-784.","DOI":"10.1016\/j.surg.2010.07.021"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2022.115373_b0280","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transpl."},{"key":"10.1016\/j.bcp.2022.115373_b0285","doi-asserted-by":"crossref","unstructured":"B.J. Allan, B. Wang, J.S. Davis, P.P. Parikh, E.A. Perez, H.L. Neville, J.E. Sola, A review of 218 pediatric cases of hepatocellular carcinoma, J Pediatr Surg 49(1) (2014) 166\u2013171; discussion 171.","DOI":"10.1016\/j.jpedsurg.2013.09.050"},{"issue":"12","key":"10.1016\/j.bcp.2022.115373_b0290","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamasurg.2015.1847","article-title":"Effect of Liver Transplant on Long-term Disease-Free Survival in Children With Hepatoblastoma and Hepatocellular Cancer","volume":"150","author":"Pham","year":"2015","journal-title":"JAMA Surg."},{"issue":"4","key":"10.1016\/j.bcp.2022.115373_b0295","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ctrv.2010.02.013","article-title":"Progress in the surgical treatment of malignant liver tumors in children","volume":"36","author":"Otte","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"29","key":"10.1016\/j.bcp.2022.115373_b0300","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1200\/JCO.2012.48.5896","article-title":"Effect of antiviral treatment with nucleotide\/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study","volume":"31","author":"Yin","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2022.115373_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101345","article-title":"HCC and Molecular Targeting Therapies: Back to the Future","volume":"9","author":"Rinaldi","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.bcp.2022.115373_b0310","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/08880018.2020.1740844","article-title":"Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective","volume":"37","author":"Pearson","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2022.115373_b0315","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","article-title":"Hep G2 is a hepatoblastoma-derived cell line","volume":"40","author":"Lopez-Terrada","year":"2009","journal-title":"Hum. Pathol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115373_b0320","doi-asserted-by":"crossref","first-page":"e38223","DOI":"10.1371\/journal.pone.0038223","article-title":"Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma","volume":"7","author":"Armeanu-Ebinger","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2022.115373_b0325","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yexcr.2014.10.018","article-title":"Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma","volume":"331","author":"Nagel","year":"2015","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0330","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1053\/j.gastro.2012.08.032","article-title":"Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice","volume":"143","author":"Zhang","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2016.04.009","article-title":"Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer","volume":"65","author":"Bissig-Choisat","year":"2016","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115373_b0340","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020273","article-title":"Animal Modeling of Pediatric Liver Cancer","volume":"12","author":"Whitlock","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2022.115373_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.942341","article-title":"CDK4\/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells","volume":"12","author":"Digiacomo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2022.115373_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.563249","article-title":"Simultaneous Combination of the CDK4\/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines","volume":"10","author":"Digiacomo","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115373_b0355","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1053\/j.gastro.2010.01.007","article-title":"Proliferative suppression by CDK4\/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells","volume":"138","author":"Rivadeneira","year":"2010","journal-title":"Gastroenterology"},{"issue":"6487","key":"10.1016\/j.bcp.2022.115373_b0360","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bcp.2022.115373_b0365","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semcdb.2019.05.012","article-title":"Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer","volume":"98","author":"Mates","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115373_b0370","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.21467","article-title":"Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets","volume":"45","author":"Boyault","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0375","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/bjc.2014.425","article-title":"Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts","volume":"111","author":"Chiu","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"44","key":"10.1016\/j.bcp.2022.115373_b0380","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1424894112","article-title":"Transcriptomic characterization of fibrolamellar hepatocellular carcinoma","volume":"112","author":"Simon","year":"2015","journal-title":"PNAS"},{"issue":"10","key":"10.1016\/j.bcp.2022.115373_b0385","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1158\/2159-8290.CD-20-0872","article-title":"Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening","volume":"11","author":"Lalazar","year":"2021","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bcp.2022.115373_b0390","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.surg.2003.11.015","article-title":"Prognostic significance of Bcl-xL in human hepatocellular carcinoma","volume":"135","author":"Watanabe","year":"2004","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.bcp.2022.115373_b0395","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115373_b0400","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","article-title":"Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216","volume":"21","author":"Thummuri","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"17","key":"10.1016\/j.bcp.2022.115373_b0405","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161820","article-title":"Targeting BCL-XL in fibrolamellar hepatocellular carcinoma","volume":"7","author":"Shebl","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2022.115373_b0410","doi-asserted-by":"crossref","first-page":"765101","DOI":"10.3389\/fimmu.2021.765101","article-title":"Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222004683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222004683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:15:59Z","timestamp":1762096559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222004683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":84,"alternative-id":["S0006295222004683"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115373","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of the art and perspectives in pediatric hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115373"}}